Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study
Authors' conclusion
Our findings highlight suboptimal adherence to amikacin monitoring guidelines in ICU patients on RRT.
Study context
- Population
- Adult ICU patients receiving their first amikacin dose while on renal replacement therapy (RRT), 18 French hospitals, April 2020 to January 2022~two-thirds continuous RRT
- Participants
- 111 patients
- Outcome
- Amikacin dosing, monitoring and simulated target attainment
Methodological detailsmulticentre, pharmacokinetic modelling and simulation
- Multicentre
- Pharmacokinetic modelling and simulation
Main finding
As reported in the abstract
Median amikacin dose (mg/kg)
27
25–30
Cmax monitored, patients (%)
53
47.8%
Trough concentration monitored, patients (%)
76
68.5%
Observational data: associations, not effects.
Original publication
Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study. Ann Intensive Care. Published 26 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →